We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data
Read MoreHide Full Article
Clinical-stage immunotherapy company, ImmunityBio, Inc. (IBRX - Free Report) , reported encouraging initial data on its COVID-19 vaccine candidate.
The data demonstrated that a single subcutaneous injection of the company’s COVID-19 vaccine candidate in healthy phase I study participants stimulates the generation of T cells that are reactive to the spike (S) and nucleocapsid (N) protein antigens delivered by the vaccine.
The magnitude of this T cell response was equivalent to those seen for S & N T cell responses from previously infected convalescent SARS-CoV-2 patients. The mean level of T cells generated in response to the hAd5 S+N T cell vaccine was ten times higher for N-specific T cells just 14-16 days after the single dose. By day 21, both S and N T cell responses achieved levels ten times higher as compared to pre-vaccination levels.
Per the company, these findings provide the potential of the hAd5 S + N T cell vaccine for use as a "Universal T Cell Booster" to enhance T cell immunity in healthy recipients of current vaccines or previously infected convalescent subjects.
The phase Ib study is ongoing to explore the safety and immunogenicity of subcutaneous, oral and sublingual prime-boost combinations of the hAd5 S + N vaccine.
The company’s shares have surged 143.7% in the year so far against the industry's decline of 6.5%.
The emerging variants of SARS-CoV-2 pose a significant threat as authorized vaccines face challenges.
Per the company, current vaccines target the S protein, leaving open the potential for antigen drift (mutation) and rendering these vaccines to be less effective against variants. ImmunityBio aims to develop the second-generation COVID-19 vaccine, which is room-temperature stable, can be self-administered orally and generates both antibody and long-term T cell immunity.
The FDA has already granted Emergency Use Authorization (EUA) to Pfizer (PFE - Free Report) /BioNTech and Moderna’s (MRNA - Free Report) vaccines for COVID-19. Last month, the FDA granted EUA to Johnson & Johnson’s (JNJ - Free Report) single-dose COVID-19 vaccine in individuals 18 years of age and older.
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Image: Bigstock
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data
Clinical-stage immunotherapy company, ImmunityBio, Inc. (IBRX - Free Report) , reported encouraging initial data on its COVID-19 vaccine candidate.
The data demonstrated that a single subcutaneous injection of the company’s COVID-19 vaccine candidate in healthy phase I study participants stimulates the generation of T cells that are reactive to the spike (S) and nucleocapsid (N) protein antigens delivered by the vaccine.
The magnitude of this T cell response was equivalent to those seen for S & N T cell responses from previously infected convalescent SARS-CoV-2 patients. The mean level of T cells generated in response to the hAd5 S+N T cell vaccine was ten times higher for N-specific T cells just 14-16 days after the single dose. By day 21, both S and N T cell responses achieved levels ten times higher as compared to pre-vaccination levels.
Per the company, these findings provide the potential of the hAd5 S + N T cell vaccine for use as a "Universal T Cell Booster" to enhance T cell immunity in healthy recipients of current vaccines or previously infected convalescent subjects.
The phase Ib study is ongoing to explore the safety and immunogenicity of subcutaneous, oral and sublingual prime-boost combinations of the hAd5 S + N vaccine.
The company’s shares have surged 143.7% in the year so far against the industry's decline of 6.5%.
The emerging variants of SARS-CoV-2 pose a significant threat as authorized vaccines face challenges.
Per the company, current vaccines target the S protein, leaving open the potential for antigen drift (mutation) and rendering these vaccines to be less effective against variants. ImmunityBio aims to develop the second-generation COVID-19 vaccine, which is room-temperature stable, can be self-administered orally and generates both antibody and long-term T cell immunity.
The FDA has already granted Emergency Use Authorization (EUA) to Pfizer (PFE - Free Report) /BioNTech and Moderna’s (MRNA - Free Report) vaccines for COVID-19. Last month, the FDA granted EUA to Johnson & Johnson’s (JNJ - Free Report) single-dose COVID-19 vaccine in individuals 18 years of age and older.
ImmunityBio currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>